首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1917737

血清學檢測市場－2026-2031年預測

Serological Testing Market - Forecast from 2026 to 2031

出版日期: 2026年01月05日 | 出版商:

Knowledge Sourcing Intelligence | 英文 150 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計血清學檢測市場將從 2025 年的 61.14 億美元成長到 2031 年的 87.27 億美元，複合年成長率為 6.11%。

血清學檢測市場是現代診斷醫學的關鍵組成部分，它透過分析血液樣本中特定的抗體、抗原和其他免疫標記物，為免疫反應提供重要資訊。這些檢測對於多種應用至關重要，包括診斷感染疾病、評估免疫狀態（疫苗接種後或感染後）、檢測自體免疫疾病以及監測慢性病。該行業服務於廣泛的終端用戶網路，主要包括醫院、臨床檢查室、血庫和公共衛生機構，所有這些機構都依賴血清學檢測的準確性和可靠性來進行病患管理、血液安全和流行病學監測。全球醫療保健環境持續存在的結構性趨勢推動了市場成長。

主要市場成長要素

市場擴張得益於多個強勁且持續的促進因素。主要成長要素是全球醫療基礎設施的持續擴張和完善，特別是新建醫院和診斷檢查室。隨著醫療網路服務範圍的擴大，診斷檢測量自然也會增加。血清學檢測是醫院檢查室診斷肝炎、愛滋病、萊姆病和德國麻疹等疾病的基礎檢測方法，也可用於術前篩檢和一般健康評估。這種基礎設施的成長直接轉化為對可靠的檢測試劑、設備和平台的需求增加。

與此密切相關的是血庫服務的策略性擴張和現代化。血清學檢測是輸血安全的重要基礎，所有捐血的血液都必須接受輸血傳染病（如愛滋病毒、B型肝炎、C型肝炎和梅毒）的強制性篩檢。在監管要求和公共衛生優先事項的雙重推動下，全球為確保血液供應安全所做的努力，正在持續且顯著地推動對篩檢檢測的需求。增加自願捐血和建立區域血液處理中心的舉措，進一步推動了這項需求。

此外，公共衛生措施和流行病學調查計畫的增加是成長要素。各國政府和國際衛生組織擴大利用指南檢測進行人群層面的研究，例如監測疾病流行情況、評估群體免疫力、指導疫苗宣傳活動以及應對疫情。血清學檢測能夠識別先前感染，使其成為公共衛生規劃和資源分配的強大工具，有助於購買用於大規模篩檢的檢測試劑。

區域展望：亞太優勢

亞太地區預計將引領全球血清學檢測市場。這一主導地位源於該地區龐大且不斷成長的人口，以及對醫療基礎設施的快速且大規模的投資。該地區許多國家正積極擴大醫院網路，提升檢測能力，並實施包括廣泛診斷篩檢在內的國家衛生計畫。政府主導的旨在改善公共衛生狀況、控制感染疾病和保障血液安全的各項舉措，持續推動對診斷檢測的顯著需求，使亞太地區成為市場成長的關鍵驅動力。

主要市場限制因素

限制更廣泛、更公平的市場進入的主要阻礙因素是先進血清學檢測的高成本，包括自動化分析儀、專用試劑組和複雜的多重檢測等相關費用。在資源匱乏的環境中，例如發展中地區和醫療資源不足的醫療系統，這些成本可能構成障礙。高昂的檢測成本會限制常規使用，阻礙最新檢測技術的普及，並造成診斷能力的缺口。這種經濟障礙使得價格敏感型細分市場的滲透更加複雜，因此亟需開發更具成本效益的解決方案，同時又不影響必要的準確性。

競爭格局與策略趨勢

該市場以大規模體外診斷（IVD）公司為特徵，這些公司提供全面的儀器、試劑和軟體產品組合。主要企業在檢測準確性、靈敏度和特異性、檢測專案廣度、自動化能力以及與實驗室資訊系統的整合等方面展開競爭。競爭格局強調檢測形式的持續創新，包括用於核心檢查室的高通量自動化系統和用於分散式環境的快速就地檢驗。

產業相關人員的策略重點領域包括：拓展檢測項目以涵蓋新發和再發病原體；提升自動化程度以提高檢查室效率並減少人為錯誤；以及開發可從單一檢體中檢測多種分析物的多重檢測方法，從而節省時間和資源。在關鍵市場獲得監管部門核准、建立強大的分銷商網路以及為檢查室客戶提供可靠的技術支持，對於成功至關重要。

未來發展與策略考量

受醫療基礎設施、血液安全和公共衛生等領域非週期性需求的推動，血清學檢測市場預計將持續成長。未來發展趨勢將受到以下因素的影響：個人化醫療的趨勢、對新興感染疾病威脅快速反應的需求，以及將血清學數據與其他診斷方法相結合以進行更全面的患者評估。

產業領導者的策略重點包括：應對複雜多變的監管環境；為高通量參考實驗室和資源匱乏地區開發分級產品系列；以及投資研發，將新型生物標記發現轉化為經臨床檢驗的檢測方法。作為診斷、篩檢和監測的基礎工具，血清學檢測仍然是臨床和公共衛生實踐的重要組成部分，其市場成長與全球擴大和改善醫療服務的努力密不可分。

本報告的主要優勢：

深入分析：提供對主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、行業垂直領域和其他細分市場。
競爭格局：了解全球主要企業的策略舉措，並了解透過正確的策略進入市場的可能性。
市場促進因素與未來趨勢：探討影響市場的動態因素和關鍵趨勢及其對未來市場發展的影響。
可操作的建議：利用洞察力並做出策略決策，在動態環境中開發新的業務流和收入來源。
受眾廣泛：適用於Start-Ups、研究機構、顧問公司、中小企業和大型企業，且經濟實惠。

以下是一些公司如何使用這份報告的範例

產業與市場分析、機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法規結構及影響、新產品開發、競爭情報

報告範圍：

2021年至2025年的實際數據和2026年至2031年的預測數據
成長機會、挑戰、供應鏈前景、法規結構與趨勢分析
競爭定位、策略和市場佔有率分析
按業務板塊和地區（包括國家）分類的收入和預測評估
公司概況（策略、產品、財務資訊、關鍵發展等）

英國血清學研究所（SERI）
Chembio Diagnostics, Inc.（美國）
Cellex（美國）
朗道實驗室有限公司（英國）
雅培（美國）
Bio-Rad Laboratories Inc.（美國）
BD（美國）
賽默飛世爾科技公司（美國）
Ortho Clinical Diagnostics（美國）
Quest Diagnostics Incorporated（美國）

第11章附錄

貨幣
先決條件
基準年和預測年時間表
相關人員的主要收益
調查方法
簡稱

簡介目錄

Product Code: KSI061615692

The serological testing market is expected to grow at a 6.11% CAGR, achieving USD 8.727 billion in 2031 from USD 6.114 billion in 2025.

The serological testing market is a critical component of modern diagnostic medicine, providing essential insights into immune response through the analysis of blood samples for specific antibodies, antigens, and other immunological markers. These tests are indispensable for a wide range of applications, including the diagnosis of infectious diseases, assessment of immune status (post-vaccination or post-infection), autoimmune disease detection, and monitoring of chronic conditions. The industry serves a broad network of end-users, primarily hospitals, clinical laboratories, blood banks, and public health agencies, all of which rely on the accuracy and reliability of serological assays for patient management, blood safety, and epidemiological surveillance. Market growth is fueled by enduring structural trends within the global healthcare landscape.

Primary Market Growth Drivers

Market expansion is underpinned by several powerful and sustained drivers. A fundamental catalyst is the ongoing global expansion and strengthening of healthcare infrastructure, particularly the establishment of new hospitals and diagnostic laboratories. As healthcare networks grow to serve larger populations, the volume of diagnostic testing inherently increases. Serological tests are a staple in hospital laboratories for diagnosing conditions like hepatitis, HIV, Lyme disease, and rubella, as well as for pre-operative screenings and general health assessments. This infrastructure growth directly translates to higher demand for reliable testing reagents, instruments, and platforms.

Closely linked is the strategic expansion and modernization of blood bank services. Serological testing is a non-negotiable pillar of blood safety, mandated for screening all donated blood for transfusion-transmissible infections such as HIV, hepatitis B and C, and syphilis. The global emphasis on ensuring a safe blood supply, driven by both regulatory mandates and public health priorities, creates a consistent, high-volume demand for serological screening assays. Initiatives to increase voluntary blood donations and establish regional blood processing centers further bolster this demand.

Furthermore, the increase in public health initiatives and epidemiological surveillance programs is a significant growth vector. Governments and international health organizations increasingly utilize serological testing for population-level studies to monitor disease prevalence, assess herd immunity, guide vaccination campaigns, and manage outbreak responses. The ability of serology to identify past infections makes it a powerful tool for public health planning and resource allocation, driving procurement of tests for large-scale screening efforts.

Geographical Outlook: Asia-Pacific Dominance

The Asia-Pacific region is estimated to dominate the global serological testing market. This projected leadership is attributed to the region's massive and growing population, coupled with rapid and large-scale investments in healthcare infrastructure. Many countries in the region are actively expanding their hospital networks, upgrading laboratory capabilities, and implementing national health programs that include widespread diagnostic screening. Government-led initiatives aimed at improving public health outcomes, controlling infectious diseases, and ensuring blood safety are creating a sustained and high-volume demand for diagnostic tests, positioning Asia-Pacific as the primary engine for market growth.

Key Market Restraint

A significant restraint on broader and more equitable market access is the high cost associated with advanced serological testing. This includes expenses related to automated analyzers, proprietary reagent kits, and sophisticated multiplex assays. In resource-constrained settings, including developing regions and underfunded healthcare systems, these costs can be prohibitive. High test costs can limit routine use, restrict access to the latest testing technologies, and create disparities in diagnostic capabilities. This economic barrier challenges market penetration in price-sensitive segments and necessitates the development of more cost-effective solutions without compromising essential accuracy.

Competitive Landscape and Strategic Dynamics

The market is characterized by the presence of large, multinational in-vitro diagnostics (IVD) corporations that offer comprehensive portfolios of instruments, reagents, and software. Key players compete on the basis of assay accuracy, sensitivity and specificity, test menu breadth, automation capabilities, and integration into laboratory information systems. The competitive landscape emphasizes continuous innovation in assay formats, including the development of high-throughput automated systems for core laboratory use and rapid point-of-care tests for decentralized settings.

Strategic focus areas for industry participants include expanding test menus to cover emerging and re-emerging pathogens, improving automation to enhance laboratory efficiency and reduce human error, and developing multiplex assays that can detect multiple analytes from a single sample to conserve time and resources. Success depends on securing regulatory approvals across key markets, establishing strong distributor networks, and providing robust technical support to laboratory customers.

Future Trajectory and Strategic Considerations

The serological testing market is poised for sustained growth, driven by the non-cyclical needs of healthcare infrastructure, blood safety, and public health. Future developments will likely be influenced by trends toward more personalized medicine, the need for rapid response to emerging infectious disease threats, and the integration of serological data with other diagnostic modalities for a more holistic patient assessment.

For industry leaders, strategic priorities will include navigating complex and evolving regulatory pathways, developing tiered product portfolios to serve both high-throughput reference labs and low-resource settings, and investing in research to translate new biomarker discoveries into clinically validated assays. As a fundamental tool for diagnosis, screening, and surveillance, serological testing will remain an indispensable element of clinical and public health practice, with its market growth inextricably linked to the global commitment to expanding and improving healthcare delivery.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2021 to 2025 & forecast data from 2026 to 2031
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Serological Testing Market Segmentation

By Test Type
Primary Serological Tests
Enzyme Linked Immunosorbent Assay (ELISA)
Immunofluorescent Antibody Technique (IFAT)
Radio Immunoassay (RIA)
Secondary Serological Tests
Agglutination Tests
Complement Fixation Tests (CFT)
Precipitation Tests
Serum Neutralization Tests (SNT)
Toxin-antitoxin Tests
Tertiary Binding Tests
By Application
Rotavirus
Hepatitis
HIV
Endotoxins
Therapeutic Drug Monitoring
Other Infectious Diseases
By End-User
Hospitals and Clinics
Diagnostic Laboratories
Blood Banks
Others
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
India
Japan
South Korea
Indonesia
Thailand
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. SEROLOGICAL TESTING MARKET BY TEST TYPE

5.1. Introduction
5.2. Primary Serological Tests
- 5.2.1. Enzyme Linked Immunosorbent Assay (ELISA)
- 5.2.2. Immunofluorescent Antibody Technique (IFAT)
- 5.2.3. Radio Immunoassay (RIA)
5.3. Secondary Serological Tests
- 5.3.1. Agglutination Tests
- 5.3.2. Complement Fixation Tests (CFT)
- 5.3.3. Precipitation Tests
5.4. Serum Neutralization Tests (SNT)
- 5.4.1. Toxin-antitoxin Tests
- 5.4.2. Tertiary Binding Tests

6. SEROLOGICAL TESTING MARKET BY APPLICATION

6.1. Introduction
6.2. Rotavirus
6.3. Hepatitis
6.4. HIV
6.5. Endotoxins
6.6. Therapeutic Drug Monitoring
6.7. Other Infectious Diseases

7. SEROLOGICAL TESTING MARKET BY END-USER

7.1. Introduction
7.2. Hospitals and Clinics
7.3. Diagnostic Laboratories
7.4. Blood Banks
7.5. Others

8. SEROLOGICAL TESTING MARKET BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. USA
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. Germany
- 8.4.2. France
- 8.4.3. United Kingdom
- 8.4.4. Spain
- 8.4.5. Others
8.5. Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Others
8.6. Asia Pacific
- 8.6.1. China
- 8.6.2. India
- 8.6.3. Japan
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others